Latest News
-
Tuesday - February 5, 2019
Not intended for U.S. and UK Media
Bayer to showcase new data from its growing cancer portfolio at 2019 ASCO GU Cancers Symposium
First presentation of data from the pivotal Phase III ARAMIS trial with the investigational compound darolutamide in patients with advanced prostate cancer that has not yet metastasized » more
-
Tuesday - February 5, 2019
Bayer announces collaborations and presents new horticulture portfolio at Fruit Logistica:
Bayer committed to fostering partnerships to advance sustainable agriculture » more
-
Thursday - January 31, 2019
Not intended for U.S. and UK Media
Bayer and Kyoto University form research alliance to discover new treatment approaches against lung diseases » more
-
Monday - January 28, 2019
No. 3 in advancing smallholder productivity and income:
Bayer maintains strong position in Access to Seeds Index » more
-
Monday - January 28, 2019
Not intended for U.S. and UK Media
Bayer to showcase latest data for its hemophilia portfolio at EAHAD 2019 Congress » more
-
Tuesday - January 22, 2019
CDP publishes new climate and water rankings:
Bayer confirms leading international position as a sustainable company in the areas of climate and water
Board of Management member Dr. Klusik: “We will continue making positive contributions to protecting the climate and water resources” / Numerous investors now use CDP ratings to help reach their investment decisions » more
- ARCHIVIERT
Wednesday - January 16, 2019
Not intended for U.S. and UK Media
Bayer to present new data for Stivarga and Nexavar at 2019 ASCO Gastrointestinal Cancers Symposium
New data includes the final analysis of the CORRELATE study assessing regorafenib in metastatic colorectal cancer, and Phase II studies of regorafenib reaffirming efficacy following treatment with chemotherapy » more
- ARCHIVIERT
Tuesday - January 8, 2019
New predictive seed placement technology delivers strong results in 2018:
Bayer expands digital innovation pipeline at The Climate Corporation to bring breakthrough digital tools to more farmers » more
- ARCHIVIERT
Thursday - December 20, 2018
A competitive advantage for Argentine soy farmers:
Bayer, RTRS and AAPRESID encourage sustainable soybean production » more
- ARCHIVIERT
Thursday - December 20, 2018
Not intended for U.S. and UK Media
Bayer receives approval in China for endometriosis treatment Visanne™ » more
- ARCHIVIERT
Tuesday - December 18, 2018
Bayer announces WHO pre-qualification for Fludora™ Fusion to combat malaria
First product for indoor residual spraying against malaria vectors to combine two modes of action. / Addresses the threat of insecticide resistant mosquitoes. / Now fully evaluated by World Health Organisation (WHO) for safety, efficacy and quality. » more
- ARCHIVIERT
Tuesday - December 18, 2018
Bayer extends credit line and increases volume to 4.5 billion euros » more
- ARCHIVIERT
Friday - December 14, 2018
Bayer and the S M Sehgal Foundation announce a new project:
Supporting livelihoods and nutrition of smallholder farmers in India » more
- ARCHIVIERT
Friday - December 7, 2018
First Anniversary of Bayer’s Transparency Initiative
Bayer committed to transparency: Posts more than 300 glyphosate safety study summaries online » more
- ARCHIVIERT
Wednesday - December 5, 2018
Capital Markets Day 2018
Bayer to drive value creation as company pursues ambitious growth targets through 2022
Company strongly positioned to benefit from key megatrends / Through 2022, Bayer aims to grow sales by 4 percent, EBITDA before special items by 9 percent and free cash flow by 18 percent annually on average / Adjusted EBITDA margin targets for 2022: Crop Science to exceed 30 percent, Pharmaceuticals to hit more than 35 percent, and Consumer Health to reach approximately 24 percent » more
- ARCHIVIERT
Monday - December 3, 2018
Chronic Thromboembolic Pulmonary Hypertension (CTEPH)
FDA grants breakthrough device designation to artificial intelligence software for CTEPH pattern recognition from Bayer and MSD
The software in development intends to support clinical decision-making of chronic thromboembolic pulmonary hypertension – a progressive and life-threatening condition » more
- ARCHIVIERT
Thursday - November 29, 2018
Group to take comprehensive range of portfolio, efficiency and structural measures
Bayer to strengthen core life science businesses while significantly enhancing productivity and profitability
Group plans to exit Animal Health business, the Consumer Health brands Coppertone™ and Dr. Scholl’s™, and sell its 60-percent interest in Currenta, a site services provider in Germany / Efficiency and structural measures set to enhance competitiveness and generate annual contributions of 2.6 billion euros as of 2022 including the expected synergies from the Monsanto acquisition / A portion of the contributions to be reinvested in core businesses / Total one-time costs expected at a factor of 1.7 times annual contributions / Core earnings per share expected to increase by around 1 euro to 6.80 euros in 2019, with a target of around 10 euros in 2022 / EBITDA margin before special items set to amount to over 30 percent in 2022 / Efficiency and structural measures expected to result in the reduction of around 12,000 of 118,200 jobs worldwide, a significant number of them in Germany » more
- ARCHIVIERT
Tuesday - November 27, 2018
Not intended for U.S. and UK Media
Bayer receives EU approval for its hemophilia A treatment Jivi®
The safety and efficacy profile of Jivi has been demonstrated in more than five years of clinical studies / Prophylaxis with Jivi enables sustained factor VIII concentrations in the blood over time » more
- ARCHIVIERT
Tuesday - November 27, 2018
Not intended for U.S. and UK Media
U.S. FDA approves Larotrectinib, the first TRK inhibitor, for patients with advanced solid tumors harboring an NTRK gene fusion
First treatment with a tumor-agnostic indication at the time of initial FDA approval / Larotrectinib approved under the brand name Vitrakvi® / 75% overall response rate (ORR) (95% CI, 61%, 85%) [22% complete response (CR) and 53% partial response (PR)] across various solid tumors in adults and children / Adverse events (AEs) of any grade observed in more than 20 percent of patients, regardless of attribution, included increased ALT (45%), increased AST (45%), anemia (42%), fatigue (37%), nausea (29%), dizziness (28%), cough (26%), vomiting (26%), constipation (23%), and diarrhea (22%) » more
- ARCHIVIERT
Wednesday - October 24, 2018
Not intended for U.S. and UK Media
Phase III trial of darolutamide in patients with non-metastatic castration-resistant prostate cancer meets primary endpoint
The safety and tolerability observed in the trial were consistent with previously published data on darolutamide » more
Copyright @ Bayer AG
Search
Publications
Newsletter
Events
Thursday, February 25, 2021
Financial News Conference on the Full Year 2020 Results
Additional Press Events
Investor Relations Events
BayKomm Events
Download Center - Selection
Bayer TV